XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer
XBiotech announced positive final Phase II results from the investigator-sponsored TASKIN trial of vilamakitug (XB2001) plus TAS-102 in refractory metastatic colorectal cancer, meeting the pre-specified efficacy success criterion with 61.3% 12-month overall survival versus 55.7% in the control arm. The exploratory subgroup analysis showed a statistically significant 62% reduction in risk of death (HR 0.38) and 61% reduction in treatment strategy failure (HR 0.39) in right-sided primary tumors, an aggressive high-need subtype. Management says the biomarker-anchored right-sided population provides a validated direction as vilamakitug advances toward registrational development.
Key figures
- Drug Name
- vilamakitug (Natrunix, XB2001)
- Phase Of Trial
- Phase 2
- Os 12mo control
- 55.7%
- Os 12mo treatment
- 61.3%
- Median pfs control
- 5.6 months
- Median pfs treatment
- 5.9 months
- Right sided os hazard ratio
- 0.38
- Right sided tsf hazard ratio
- 0.39
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.